![Peter Salzmann](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Peter Salzmann
Directeur Général chez
IMVT Corp.
Fortune : 38 M $ au 30/09/2026
Profil
Peter Salzmann is currently Chief Executive Officer at IMVT Corp.
since 2019.
He is also a Director at Corbus Pharmaceuticals, Inc. and a Director at Immunovant Sciences Ltd., both positions starting in 2019.
Formerly, Dr. Salzmann was Chief Executive Officer at Immunovant, Inc. in 2025.
He was an Independent Director at Corbus Pharmaceuticals Holdings, Inc. from 2020 to 2025.
From 2013 to 2019, he was Head-Immunology at Eli Lilly & Co. From 2008 to 2010, he was Head-Marketing at Eli Lilly Asia.
, Inc. Education includes an undergraduate degree from Northwestern University, an MBA from Stanford Graduate School of Business, and a doctorate from Pritzker School of Medicine.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
IMMUNOVANT INC 0,54 % | 30/06/2026 | 1 112 193 ( 0,54 % ) | 38 M $ | 30/09/2026 |
Postes actifs de Peter Salzmann
| Sociétés | Poste | Début |
|---|---|---|
Corbus Pharmaceuticals, Inc.
 Corbus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company | Directeur/Membre du Conseil | - |
IMVT Corp. | Directeur Général | 01/06/2019 |
Immunovant Sciences Ltd.
 Immunovant Sciences Ltd. BiotechnologyHealth Technology Develops restorative therapies for autoimmune diseases | Directeur/Membre du Conseil | 01/10/2019 |
Anciens postes connus de Peter Salzmann
| Sociétés | Poste | Fin |
|---|---|---|
| CORBUS PHARMACEUTICALS HOLDINGS, INC. | Directeur/Membre du Conseil | 15/05/2025 |
| IMMUNOVANT, INC. | Directeur Général | 20/04/2025 |
| ELI LILLY AND COMPANY | Corporate Officer/Principal | 01/06/2019 |
Eli Lilly Asia, Inc. | Sales & Marketing | 01/12/2010 |
Formation de Peter Salzmann
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
77
Relations au 1er degré
10
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 10 |
|---|---|
Eli Lilly & Co.
 Eli Lilly & Co. Pharmaceuticals: MajorHealth Technology Manufactures, wholesales and markets pharmaceutical products | Health Technology |
Corbus Pharmaceuticals, Inc.
Corbus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company | Health Technology |
Northwestern University
 Northwestern University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Eli Lilly Asia, Inc. | |
Stanford Graduate School of Business
 Stanford Graduate School of Business Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Pritzker School of Medicine
 Pritzker School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Corbus Pharmaceuticals Holdings, Inc.
 Corbus Pharmaceuticals Holdings, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases | Health Technology |
Immunovant Sciences Ltd.
Immunovant Sciences Ltd. BiotechnologyHealth Technology Develops restorative therapies for autoimmune diseases | Health Technology |
Immunovant, Inc.
 Immunovant, Inc. BiotechnologyHealth Technology Develops restorative therapies for autoimmune diseases | Health Technology |
IMVT Corp. |
